The KEYNOTE-811 trial evaluated the efficacy of pembrolizumab in combination with anti-HER2 therapy (trastuzumab) as a first-line chemotherapy strategy for patients with HER2-positive advanced gastric cancer compared with placebo [62,63]. The gene discussed is ERBB2; the disease is gastric cancer.